Alaunos Therapeutics, Inc. (TCRT) |
|
0.4713 -0.001 (-0.23%)
|
03-24 16:00 |
|
Open: |
0.4932 |
Pre. Close: |
0.4724 |
|
High:
|
0.4932 |
Low:
|
0.4583 |
|
Volume:
|
338,577 |
Market Cap:
|
113(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:24 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.68 One year: 0.78 |
| Support: |
Support1: 0.45 Support2: 0.37 |
| Resistance: |
Resistance1: 0.58 Resistance2: 0.67 |
| Pivot: |
0.51  |
| Moving Average: |
MA(5): 0.47  MA(20): 0.52
MA(100): 0.71 MA(250): 1.05 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.1 %D(3): 15.4 |
| RSI: |
RSI(14): 31.5 |
| 52-week: |
High: 4.01 Low: 0.4 |
| Average Vol(K): |
3-Month: 915 (K) 10-Days: 711 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TCRT ] has closed above bottom band by 26.8%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.49 - 0.5 |
0.5 - 0.5 |
|
Low:
|
0.45 - 0.46 |
0.46 - 0.46 |
|
Close:
|
0.47 - 0.47 |
0.47 - 0.48 |
|
Company Description |
|
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas. |
Headline News |
Mon, 13 Mar 2023
Having purchased US$813k worth of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock, the recent 12% pullback is not what insiders may have expected - Simply Wall St
Fri, 10 Mar 2023
Q1 2023 EPS Estimates for Alaunos Therapeutics, Inc. Increased by ... - MarketBeat
Wed, 08 Mar 2023
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript - Yahoo Finance
Tue, 07 Mar 2023
Ziopharm: Q4 Earnings Snapshot - Danbury News Times
Tue, 07 Mar 2023
Ziopharm: Q4 Earnings Snapshot - Jacksonville Journal-Courier
Tue, 07 Mar 2023
Alaunos Therapeutics, Inc. Tops Q4 EPS by 1c By Investing.com - Investing.com Australia
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
241 (M) |
|
% Held by Insiders
|
1.7717e+008 (%) |
|
% Held by Institutions
|
8.9 (%) |
|
Shares Short
|
24,090 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.998e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
120.4 |
|
Return on Equity (ttm)
|
-25.7 |
|
Qtrly Rev. Growth
|
2.92e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-520.74 |
|
EBITDA (p.s.)
|
1.36667e+007 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-29 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.356e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
